EMA finds GLP-1 diabetes drugs safe to use

Eric Palmer Earlier this year, a study linked the GLP-1 class of drugs for Type 2 diabetes to an increased risk of pancreatic cancer. Today, the European Medicines Agency said the data ...

EMA Decides That Diabetes Drug Are Not Linked To Pancreatic Cancer

esilverman In a decision that is a big boost to several drugmakers, the European Medicines Agency has concluded that there is no evidence to confirm recent concerns that a ...

AstraZeneca, Bristol resubmit NDA for diabetes therapy dapagliflozin

Emily Mullin AstraZeneca and Bristol-Myers Squibb are trying once again to get U.S. approval for their drug dapagliflozin, an innovative but potentially risky treatment for Type 2 diabetes. FierceBiotech ...

U.K. pharma group’s cannabis-based diabetes drug sparks insulin output

Ryan McBride GW Pharmaceuticals has expanded mindsets about potential diabetes treatment. In a small midstage study of patients on its pot-based drug candidate, the U.K. drug developer ...

Healthrageous, United BioSource And Boehringer Ingelheim Launch SMART Digital Diabetes Study

barbara.lempert BOSTON and INGELHEIM, Germany, July 16, 2013 /PRNewswire/ — Healthrageous, Inc., a digital health management company, and Boehringer Ingelheim, announced today ...

J&J, others back ViaCyte’s stem cell therapy for diabetes in $10.6M round

Ryan McBride The San Diego startup scored $ 10.6 million from the sale of stock and warrants to backers such as Johnson & Johnson Development Corporation, Asset Management Company ...

Roche Scuttles Diabetes Drug After Clinical Trial Flops

esilverman In a setback to Roche, the drugmaker has ended a Phase III trial of a high-profile diabetes compound after a data and safety monitoring board determined there were ...

Roche scraps diabetes drug as pRED racks up another PhIII fiasco

John Carroll Once again, Roche's pRED group has a big Phase III snafu to answer for. The Basel-based R&D side of the pharma giant–distinct from the gRED operations at ...

Roche Stops Diabetes Trials Over Safety Concerns

barbara.lempert Roche halts investigation of aleglitazar following regular safety review of phase III trial BASEL, Switzerland, July 10, 2013 – Roche (SIX: RO, ROG; OTCQX: ...

New Data from MSDC Outlines New Diabetes Target

mia.burns Metabolic Solutions Development Company announces publication of data  describing a new drug target for diabetes   Modulating mTOT may represent a new way forward to treat ...

‘Reverse’ DNA vaccine bursts into the spotlight with promising Type 1 diabetes data

John Carroll A stealth biotech spun out of Stanford University burst into public view today, drawing headlines around the world for its new therapeutic approach to Type 1 diabetes that ...

Isis steals diabetes drug spotlight with new approach to slashing blood fat

John Carroll In an R&D field typically characterized by slow progress and incremental gains, Isis Pharmaceuticals jumped out of the ADA pack in Chicago with some stellar mid-stage ...
Page 5 of 8« First...34567...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS